阿尔茨海默病(AD)是一种不可逆的、进行性神经退行性疾病,占老年痴呆病例的62%。早期诊断是成功治疗的关键,以减缓疾病进展,避免恶化。目前的AD诊断工具无法在早期发现该病;此外,它们仍然有一些限制。许多研究表明,microRNAs (miRNAs)与AD的发病机制有关,其在血液中的水平的改变使其成为AD的潜在生物标志物。我们的目的是评价血浆microRNA-483-5p作为轻度认知障碍(MCI)期AD早期诊断的非侵入性生物标志物,以改善治疗结果。对40例MCI和AD患者及20例明显健康对照进行了研究。采用实时聚合酶链反应(PCR)检测血浆中miRNA -483-5p水平,并以倍变形式表达。采用受试者工作特征(ROC)曲线分析评价该方法的诊断性能。MCI和AD患者血浆miRNA-483-5p水平高于对照组(均数分别为8.04、2.84和0.21,P<0.001),而AD患者血浆miRNA-483-5p水平低于MCI患者(均数分别为2.84和8.04,P = 0.032)。 There were significant positive correlations between plasma levels of miRNA-483-5p and age (r = 0.338, P= 0.008) and Dementia Rating (DR) scale (r = 0.351, P = 0.026), and significant negative correlations between plasma levels of miRNA-483-5p and Functional Daily Living Activity (FDLA) scale (r = -0.441, P<0.001), Mini Mental State Examination(MMSE) (r = -0.478, P< 0.001) and Montreal Cognitive Assessment (MOCA) scale (r = -0.396, P= 0.002). ROC curves revealed that miRNA-483-5p has high diagnostic performance in differentiating MCI and AD patients from healthy controls with specificity 95%, 90% and sensitivity 85%, 90% respectively. In conclusion, miRNA-483-5p may be a promising non -invasive biomarker for early diagnosis of AD in MCI stage.

参考

PubMed